Amir Mortazavi

Amir Mortazavi's work focuses on genitourinary (urinary and reproductive system) cancers, including bladder/urothelial, kidney (renal cell), and prostate cancer. Much of the research involves clinical trials and real-world outcome studies testing immunotherapy drugs (like checkpoint inhibitors nivolumab and ipilimumab), targeted therapies (such as cabozantinib and tyrosine kinase inhibitors), and antibody-drug conjugates (like enfortumab vedotin and sacituzumab govitecan), often in combination regimens for advanced or metastatic disease. The group also contributes to clinical practice guidelines and studies treatment side effects and resistance mechanisms.

Publication output has fluctuated over the past decade with a notable spike in 2023, following a period of moderate, steady activity in prior years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026